FDA Investigator

Wei Wang

Latest inspection on record: Woburn, United States, April 2025 · records back to 2017

Biologics

FDA inspection record · Last updated July 12, 2026

Overview

  • 16 inspections across 16 sites are on record.
  • 0 Form 483 observations are attributed to this investigator.
  • Most recent recorded activity is 2025-04-24.

At a glance

Inspections

16

Sites

16

Observations

0

Career since

Feb 2017

Recent inspections

Most recent inspections in the published record.

SiteDateCategoryForm 483
Replimune, Inc.24 Apr 2025BiologicsOn file
Replimune Limited26 Mar 2025BiologicsOn file
Bavarian Nordic Berna GmbH18 Oct 2024Biologics
Grand River Aseptic Manufacturing, Inc.19 Sep 2024BiologicsOn file
EdgeOne Medical Inc.5 Sep 2024Biologics

Sites inspected

Replimune, Inc.Woburn, United States1 insp.
Replimune LimitedOxford, United Kingdom1 insp.
Bavarian Nordic Berna GmbHThorishaus, Switzerland1 insp.
Grand River Aseptic Manufacturing, Inc.Grand Rapids, United States1 insp.
EdgeOne Medical Inc.Wheeling, United States1 insp.

Co-investigators

Investigators who share inspections with this person.

Bo Liang2 shared
Anna R Kwilas2 shared
Carl A Perez2 shared
Michael B Havert2 shared
Carla A Lorenzo1 shared
Guo-Chiuan Hung1 shared

Full investigator report

Get the verbatim findings behind Wei Wang's inspection record

Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.

  • New inspections and Form 483s, mapped to the CFR citation
  • Warning letter outcomes, and the citation patterns they repeat
  • Their co-investigators, so no surprises about who shows up on site